Repurposing Niclosamide to Modulate Renal RNA-Binding Protein HuR for the Treatment of Diabetic Nephropathy in db/db Mice

Lili Zhuang, Wenjing Liu, Xiao-Qing E. Tsai, Connor Outtrim, Anna Tang, Zhou Wang, Yufeng HuangInternational Journal of Molecular Sciences 2024 · DOI

TL;DR

This study investigates niclosamide (NCS), an existing drug, as a potential treatment for diabetic nephropathy (DN) by targeting the RNA-binding protein HuR. They found that NCS effectively reduced key markers of DN progression in a mouse model, including hyperglycemia, kidney damage, inflammation, and oxidative stress, suggesting a promising new therapeutic avenue.

What Problem Does This Paper Address?

Diabetic kidney disease (DKD) is a major cause of end-stage renal disease, and current treatments, while helpful, don't halt its progression for many patients. DKD is characterized by complex metabolic issues leading to oxidative stress and chronic inflammation. The RNA-binding protein HuR has been identified as a key player in regulating genes involved in DN pathogenesis. However, existing DKD treatments don't directly address elevated HuR levels, highlighting a need for novel therapeutic targets. This paper explores whether niclosamide (NCS), a known drug with an established safety profile, can act as an HuR inhibitor to treat DN.

Methods

The researchers utilized a well-established mouse model for type 2 diabetes and nephropathy: the uninephrectomized db/db mouse. They divided these mice into several groups: a normal control group, untreated db/db mice at different time points (14 and 22 weeks), and db/db mice treated with niclosamide (NCS) via intraperitoneal injection from week 18 to 22.

Key techniques employed included:

  • Immunofluorescence staining: To visualize and quantify the expression and localization of HuR and other proteins like collagen IV, nephrin, and WT-1 in kidney tissue.
  • Western blotting: To measure the protein levels of various markers related to fibrosis (fibronectin, alpha-smooth muscle actin), inflammation (NF-κB p65), oxidative stress (Nox2), and signaling pathways (Angiopoietin 1 & 2, Wisp1).
  • Real-time RT-PCR: To assess the mRNA expression levels of genes involved in fibrosis (fibronectin, collagen I, collagen IV) and Wisp1.
  • Clinical parameter measurements: Including body weight, blood glucose, HbA1c, urine volume, urine albumin excretion (UAE), blood urea nitrogen (BUN), and creatinine.
  • Histological analysis: Using Periodic Acid Schiff (PAS) staining to evaluate glomerular size and extracellular matrix (ECM) deposition.

Datasets

Not discussed in the paper. The study relies on experimental data generated from mouse models.

Key Insights and Ideas

  • HuR is a key culprit in DN: The study strongly implicates elevated HuR expression in the progression of diabetic kidney damage.
  • NCS is a potent HuR inhibitor in vivo: Niclosamide effectively reduced HuR levels in the kidneys of diabetic mice, demonstrating its therapeutic potential beyond its known anthelmintic properties.
  • NCS tackles multiple DN facets: The drug didn't just target HuR; it also improved hyperglycemia, reduced kidney hypertrophy and fibrosis, preserved podocyte function, and mitigated inflammation and oxidative stress. This multi-pronged approach is crucial for a complex disease like DKD.
  • Wisp1 as a downstream mediator: The identification of Wisp1 as a key downstream target of HuR-dependent action in DN provides a more granular understanding of the molecular mechanisms at play. NCS's ability to normalize Wisp1 levels further supports its therapeutic role.
  • Repurposing potential: The study highlights the significant potential of repurposing existing, safe drugs like niclosamide for complex chronic diseases, offering a faster path to clinical application.

Key Results

  • HuR levels increased in diabetic kidneys: db/db mice showed significantly higher HuR protein levels in their kidneys compared to normal controls, which were reduced by NCS treatment.
  • Improved glycemic control: NCS treatment led to a significant reduction in HbA1c levels (from 13.3% to 10.8%) in db/db mice, indicating improved blood glucose management.
  • Reduced albuminuria: NCS treatment halted the progressive increase in urinary albumin excretion, a key indicator of kidney damage.
  • Mitigated kidney damage: NCS reduced glomerular hypertrophy, glomerulosclerosis, and the deposition of fibrotic markers like fibronectin and collagen IV. It also restored nephrin expression and podocyte numbers.
  • Reduced inflammation and oxidative stress: NCS treatment significantly decreased markers of inflammation (NF-κB p65, TNF-α, MCP-1) and oxidative stress (MDA, Nox2).
  • Normalized Angiopoietin balance: NCS improved the imbalance between Angiopoietin 1 and 2, suggesting a benefit for renal endothelial function.
  • Decreased Wisp1 expression: NCS treatment normalized the elevated mRNA and protein levels of Wisp1, a key HuR target involved in fibrosis.

Limitations and Future Work

  • Low bioavailability of NCS: The authors acknowledge that NCS has low oral bioavailability, which is why they used intraperitoneal administration. Future work should focus on developing formulations or delivery methods to overcome this limitation for oral administration.
  • Cell-type specificity of HuR elevation: While HuR elevation was observed in diabetic kidneys, the specific cell types involved were not definitively identified. Further research could pinpoint which kidney cells are most affected by HuR dysregulation.
  • Long-term safety and efficacy: Although NCS has a long history of safe use as an anthelmintic, its long-term safety and efficacy specifically for DKD require further investigation in clinical trials.
  • Pancreatic effects: The study suggests NCS might also improve pancreatic islet function, contributing to glucose control. This warrants further investigation into the drug's effects on the pancreas in the context of diabetes.
  • Mechanisms of glucose lowering: While NCS improved glucose levels, the precise mechanisms underlying this effect in the context of DN are not fully elucidated and could be a focus for future research.

Summary updated

Abstract

Hu antigen R (HuR) plays a key role in regulating genes critical to the pathogenesis of diabetic nephropathy (DN). This study investigates the therapeutic potential of niclosamide (NCS) as an HuR inhibitor in DN. Uninephrectomized mice were assigned to four groups: normal control; untreated db/db mice terminated at 14 and 22 weeks, respectively; and db/db mice treated with NCS (20 mg/kg daily via i.p.) from weeks 18 to 22. Increased HuR expression was observed in diabetic kidneys from db/db mice, which was mitigated by NCS treatment. Untreated db/db mice exhibited obesity, progressive hyperglycemia, albuminuria, kidney hypertrophy and glomerular mesangial matrix expansion, increased renal production of fibronectin and a-smooth muscle actin, and decreased glomerular WT-1<sup>+</sup>-podocytes and nephrin expression. NCS treatment did not affect mouse body weight, but reduced blood glucose and HbA1c levels and halted the DN progression observed in untreated db/db mice. Renal production of inflammatory and oxidative stress markers (NF-κBp65, TNF-a, MCP-1) and urine MDA levels increased during disease progression in db/db mice but were halted by NCS treatment. Additionally, the Wnt1-signaling-pathway downstream factor, Wisp1, was identified as a key downstream mediator of HuR-dependent action and found to be markedly increased in db/db mouse kidneys, which was normalized by NCS treatment. These findings suggest that inhibition of HuR with NCS is therapeutic for DN by improving hyperglycemia, renal inflammation, and oxidative stress. The reduction in renal Wisp1 expression also contributes to its renoprotective effects. This study supports the potential of repurposing HuR inhibitors as a novel therapy for DN.
BibTeX
@article{zhuang2024repurposing,
  author = {Lili Zhuang and Wenjing Liu and Xiao-Qing E. Tsai and Connor Outtrim and Anna Tang and Zhou Wang and Yufeng Huang},
  title = {{Repurposing Niclosamide to Modulate Renal RNA-Binding Protein HuR for the Treatment of Diabetic Nephropathy in db/db Mice}},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25179651},
}
Figure